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PCLINICAL RESEARCH Clinical Trial
Randomized Early Versus Late Abciximab
in Acute Myocardial Infarction Treated With
Primary Coronary Intervention (RELAx-AMI Trial)
Mauro Maioli, MD, Francesco Bellandi, MD, Mario Leoncini, MD, Anna Toso, MD,
Roberto Piero Dabizzi, MD
Prato, Italy
Objectives This prospective randomized trial evaluates the impact of early abciximab administration on angiographic and
left ventricular function parameters.
Background Glycoprotein IIb/IIIa inhibitors improve myocardial reperfusion in patients with acute myocardial infarction (AMI)
undergoing primary percutaneous coronary intervention (PCI), but optimal timing of administration remains unclear.
Methods Two-hundred ten consecutive patients with first AMI undergoing primary PCI were randomized to abciximab ad-
ministration either in the emergency room (early group: 105 patients) or in the catheterization laboratory, after
coronary angiography (late group: 105 patients). Primary end points were initial Thrombolysis In Myocardial In-
farction (TIMI) flow grade, corrected TIMI frame count (cTFC), and myocardial blush grade (MBG), as well as left
ventricular function recovery as assessed by serial echocardiographic evaluations.
Results Angiographic pre-PCI analysis showed a significantly better initial TIMI flow grade 3 (24% vs. 10%; p  0.01),
cTFC (78  30 frames vs. 92  21 frames; p  0.001), and MBG 2 or 3 (15% vs. 6%; p  0.02) favoring the
early group. Consistently, post-PCI tissue perfusion parameters were significantly improved in the early group, as
assessed by 60-min ST-segment reduction70% (50% vs. 35%; p  0.03) and MBG 2 or 3 (79% vs. 58%; p 
0.001). Left ventricular function recovery at 1 month was significantly greater in the early group (mean gain ejection
fraction 8  7% vs. 6  7%, p  0.02; mean gain wall motion score index 0.4 0.3 vs. 0.3  0.3, p  0.03).
Conclusions In patients with AMI treated with primary PCI, early abciximab administration improves pre-PCI angiographic
findings, post-PCI tissue perfusion, and 1-month left ventricular function recovery, possibly by starting early
recanalization of the infarct-related artery. (J Am Coll Cardiol 2007;49:1517–24) © 2007 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.12.036w
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envestigations on glycoprotein IIb/IIIa inhibition in acute
T-segment elevation myocardial infarction (STEMI)
reated with primary percutaneous coronary intervention
PCI) have shown the efficacy of abciximab in improving
linical and angiographic outcome (1–5), reflected in a class
Ia recommendation in both the current European Society
f Cardiology and American College of Cardiology/
merican Heart Association guidelines on the management
f STEMI. Adjunctive abciximab therapy is associated with
significant reduction in 30-day reinfarction and in short-
nd long-term mortality in patients with STEMI treated
ith primary angioplasty (6). Moreover, early administra-
ion of abciximab in STEMI, before arrival in the catheter-
zation laboratory, appeared to improve coronary patency
rom the Division of Cardiology, Misericordia e Dolce Hospital, Prato, Italy.e
Manuscript received July 27, 2006; revised manuscript received December 6, 2006,
ccepted December 10, 2006.ith superior pre-PCI Thrombolysis In Myocardial Infarc-
ion (TIMI) flow grade 3 compared with late administration
7). However, the impact of abciximab on myocardial
erfusion has not yet been well established. In this prospec-
ive randomized trial on patients with acute myocardial
nfarction (AMI) treated with primary stenting, we evalu-
ted the impact on angiographic outcome, microvascular
eperfusion, myocardial salvage, and left ventricular (LV)
unction of abciximab administered in the emergency room
ompared with abciximab administered in the catheteriza-
ion laboratory.
ethods
opulation and trial protocol. Consecutive patients with
rst AMI candidates for primary PCI, irrespective of age,
resenting within 12 h of symptom onset with ST-segment
levation of more than 1mm in at least 2 contiguous leads of the
lectrocardiogramwere considered for randomization. Comput-
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Early Versus Late Abciximab in Primary PCI April 10, 2007:1517–24erized open-label randomization
assignments in blinded envelopes
were used in a consecutive fashion
in the emergency room.
From June 2003 to March
2006, 232 consecutive patients
with AMI were directly referred
to our hospital, which provides a
round-the-clock service of pri-
mary PCI, with 4 trained physi-
cians and dedicated nurses. Two-
hundred ten patients with first
AMI were enrolled: 105 patients
were randomly assigned to the
early group and 105 to the late
group. Twenty-two patients
were excluded. Exclusion criteria
were previous myocardial infarc-
tion; previous PCI or coronary
artery bypass surgery; left bundle
branch block; bleeding diathesis;
administration of thrombolytic
agents for the current episode;
recent stroke; uncontrolled hy-
pertension; recent surgery; oral
nticoagulant therapy; and known contraindications to ther-
py with abciximab, aspirin, clopidogrel, or heparin. To
etter analyze regional and global LV function after the
ndex event, we excluded patients with previous AMI who
ikely had pre-existent asynergies. Stent implantation was
uccessfully completed in all patients; the choice of stent
bare-metal stent or drug-eluting stent) was left to the
perator’s discretion. We attempted direct stenting only in
ases presenting clear pictures of the arterial lesion. Other-
ise, the patient is subjected to angioplasty, and stenting is
one subsequently. The protocol was approved by the
nstitutional ethics committee, and all eligible patients gave
nformed consent. The first 55 patients enrolled underwent
scintigraphic evaluation before and after PCI; the results
f the scintigraphic study were recently published (8). The
resent study represents the final report of the trial.
Randomized patients received abciximab (0.25 mg/kg as
bolus followed by a 12-h infusion of 0.125 g/kg/min)
ither in the emergency room (early group) or in the
atheterization laboratory after diagnostic angiography just
efore PCI (late group). After randomization, all patients
eceived heparin as a bolus of 70 U/kg (maximum 7,000 U)
ogether with 250 mg of aspirin intravenously, in the
mergency room. If necessary, additional boluses of heparin
ere administered to achieve an activated clotting time of
00 s. After PCI, a 24-h infusion of 7 U/kg/h of heparin
as performed. The target activated partial-thromboplastin
ime was between 1.5 and 2.0 times the control value.
mmediately after the procedure, all patients received clo-
idogrel (300 mg). Patients were routinely treated with
Abbreviations
and Acronyms
AMI  acute myocardial
infarction
cTFC  corrected
Thrombolysis In Myocardial
Infarction frame count
EF  ejection fraction
IRA  infarct-related artery
LV  left ventricle/
ventricular
MACE  major adverse
cardiac events
MBG  myocardial blush
grade
PCI  percutaneous
coronary intervention
STEMI  ST-segment
elevation myocardial
infarction
TIMI  Thrombolysis In
Myocardial Infarction
WMSI  wall motion score
indexspirin (100 mg/day indefinitely) and clopidogrel (75 mg/ iay for at least 1 month). After discharge, patients entered
clinical follow-up.
nvasive procedure and angiographic evaluation. Coro-
ary angiography was performed by the femoral approach.
ll patients underwent primary PCI and stenting of the
nfarct-related artery (IRA) according to standard tech-
ique. Initial and postprocedural TIMI flow grade, cor-
ected TIMI frame count (cTFC), and myocardial blush
rade (MBG) of the IRA were assessed off-line by a blinded
xperienced interventionalist (A.T.), as previously described
9–11). Quantitative coronary angiography (QCA) was
erformed with a use of an automatic edge detection system
Siemens Acom Quantcor QCA, Munich, Germany). Pro-
edural success was defined as residual stenosis 20% and
IMI flow grade 3 (12).
lectrocardiographic, echocardiographic, and metabolic
ata. The 12-lead electrocardiogram was recorded at pre-
entation, immediately before PCI, and continuously 180
in after coronary artery recanalization. Sum of ST-
egment elevations was measured in 3 contiguous leads with
he highest ST-segment elevation. ST-segment elevation
as measured to the nearest 0.5 mm at 60 ms after the
point with the aid of hand-held calipers. ST-segment
esolution (before and within 60 min after PCI) was defined
s the ratio between pre-intervention or post-intervention
alues and initial sum of ST-segment elevation. According
o a previous report (13), complete ST-segment resolution
as defined as a70% decrease in ST-segment elevation 60
in after recanalization of the IRA.
Left ventricular ejection fraction (EF) was assessed by
chocardiography (Sonos 5500, Agilent Technologies Inc.,
alo Alto, California) according to Simpson in classical 2-
nd 4-chamber apical projections, at arrival in the emer-
ency room and at 1-month follow-up. Wall motion was
cored 1 through 5 according to a 16-segment model, and
all motion score index (WMSI) was calculated as the sum
f segmental score divided by the number of visualized
egments (14). Electrocardiographic and echocardiographic
nalysis was performed by the investigator who was blinded
o the randomization.
Creatine kinase (CK), its myocardial fraction (CK-MB),
lasma cardiac troponin I, and myoglobin measurements
ere systematically assessed at admission, immediately be-
ore diagnostic angiography, at 30 min, 60 min, 90 min, and
very 3 h for the subsequent 24 h after PCI, then every day
p to discharge, unless clinical events suggested repeat
easurements. The peak value and 48-h cumulative release
or these serum cardiac markers were measured for the
stimation of infarct size in each patient (15).
nd points of the trial and definitions. The primary end
oint of the trial was the pre-interventional angiographic
nding evaluated in terms of TIMI flow grade. In addition,
e analyzed cTFC and MBG. Secondary end points were
nfarct size (measured by cumulative release of serum cardiac
arkers) and LV functional recovery at 1 month (evaluatedn terms of echocardiographic EF and WMSI).
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April 10, 2007:1517–24 Early Versus Late Abciximab in Primary PCIMajor and minor bleeding were defined according to the
IMI criteria (9). Platelet counts were also monitored for
hrombocytopenia, defined as a platelet count of 100,000/
m3. Major adverse cardiac events (MACE) included
eath, recurrent myocardial infarction, repeat PCI, coronary
rtery bypass surgery, and stroke. Recurrent myocardial
nfarction was defined as a new increase in CK-MB fraction
f more than 3 times of the upper limit of normal, whether
ccompanied by chest pain and/or electrocardiographic
hanges. Urgent revascularization was defined as a repeated
oronary revascularization or coronary artery bypass grafting
erformed within 24 h after the index revascularization
rocedure. Procedural time was defined as time from an-
iography to implantation of stent.
tatistical analysis. SAMPLE SIZE CALCULATION. The pri-
ary hypothesis of the trial was that early pretreatment at
mergency room with abciximab will increase the incidence
f TIMI flow grade 3 at initial angiography before PCI,
ompared with periprocedural abciximab administration. It
as expected that early treatment with abciximab would
esult in an increase in TIMI flow grade 3 from 10% to 20%.
ith 80% power, and an  value of 0.05, 95 patients were
ecessary in each group to show a significant difference in
ncidence of the primary end point. With regard to drop-
uts, at least 105 patients were planned to be included in
oth groups.
INAL ANALYSIS. Categorical variables were presented as
ounts and proportions (percentages) and compared by
earson chi-square analysis or Fisher exact test when the
alculated sample size of at least 1 cell of a table was 5.
Figure 1 Flow of Patients Through the Trial
AMI  acute myocardial infarction; CABG  coronary artery bypass grafting;
LBBB  left bundle branch block; PCI  percutaneous coronary intervention.ormal distribution of continuous data was tested using a
aolmogorov-Smirnov test. Continuous and normally dis-
ributed data are presented as mean  1 SD and were
ompared by unpaired t test; non-normally distributed data
re expressed as median with interquartile range, and the
ann-Whitney U test was used to compare differences
etween 2 groups. Multivariate logistic regression analysis
as performed using all potentially relevant variables to
dentify baseline independent predictors of initial TIMI
ow grade 3. The comparison between basal and 1 month
chocardiographic data was performed only in surviving
atients. All p values are 2-tailed, and statistical significance
as defined as a value of p  0.05. All analyses were
erformed with SPSS version 13.0 (SPSS Inc., Chicago,
llinois) statistical software.
esults
ur population is represented by 210 patients who under-
ent primary PCI treated with abciximab; 105 patients
ere randomly assigned to the early group and 105 to the
ate group. Figure 1 shows the trial flow and Table 1 the
aseline characteristics of the 2 groups. The majority of
atients were “not low risk,” according to the TIMI criteria
9). Killip class 3 or 4 was found at presentation in 5 patients
5%) of the early group and in 6 patients (6%) of the late
roup. No significant difference between groups was found
n the onset of symptoms to hospital admission time and in
he door to balloon time. As expected, the median time
etween hospital admission and abciximab bolus adminis-
aseline Clinical Characteristics of the Patients
Table 1 Baseline Clinical Characteristics of the Patients
Early Group
(n  105)
Late Group
(n  105) p Value
Age (yrs) 64 10 66 12 NS
Age 75 yrs (%) 17 (16) 26 (25) NS
Female gender (%) 25 (24) 27 (26) NS
Risk factor, n (%)
Hypertension 51 (49) 48 (46) NS
Diabetes mellitus 31 (29) 31 (29) NS
History of smoking 45 (43) 54 (51) NS
Hyperlipidemia 43 (41) 41 (39) NS
Low-risk patients 36 (34) 43 (41) NS
Killip class 2 (%) 20 (21) 25 (26) NS
Infarct artery, n (%) NS
Right coronary artery 44 (42) 40 (38)
Circumflex artery 9 (9) 12 (11)
Left anterior descending 52 (49) 52 (49)
Main vessel 0 1 (1)
Multivessel disease, n (%) NS
2-vessel 32 (30) 40 (38)
3-vessel 22 (21) 25 (24)
Symptom onset to admission (min) 85 (59–160) 105 (63–170) NS
Door to abciximab (min) 23 (15–37) 60 (40–88) 0.001
Door to balloon (min) 84 (67–107) 73 (59–104) NS
Start of abciximab to balloon (min) 55 (46–72) 14 (11–18) 0.001
ata are presented as mean value SD or number (%) of patients; procedural times are presented
s median with interquartile ranges.
NS  not significant.
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MBG  myocardial blush grade; NS  not significant; TIMI  Thrombolysis In Myocardial
Infarction.
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Early Versus Late Abciximab in Primary PCI April 10, 2007:1517–24ration was significantly shorter in the early group (23 min,
nterquartile range 15 to 37 min) than in the late group (60
in, interquartile range 40 to 88 min). The early treatment
roup received the abciximab bolus on a median of 55 min
interquartile range 46 to 72 min) before angioplasty (Table 1).
djunctive therapy received by each treatment group did
ot differ.
ngiographic and procedural results. Angiographic and
rocedural results are summarized in Table 2. Angiographic
re-PCI analysis showed a significant difference in initial
IMI flow grade 3 (early group 24% vs. late group 10%; p
.01), cTFC, and MBG 2 or 3, favoring the early group
Table 2, Fig. 2). Direct stenting was feasible in 29% of
atients of the early group versus 13% of the late group (p
.004), and the procedural time was significantly shorter in
he early group (early group 11  7 min vs. late group 15 
min; p  0.03). Multivariate analysis identified only early
bciximab administration (odds ratio 2.90; 95% confidence
nterval 1.3 to 6.6; p  0.01) as an independent predictor of
nitial TIMI flow grade 3. No differences were found in the
ost-PCI IRA patency (92% of TIMI flow grade 3 in both
roups), and no significant difference was observed in the
nal cTFC (Table 2). On the contrary, final MBG 2 or 3
as achieved in a significant higher proportion of the early
roup (79% vs. 58% of the late treatment group; p 0.001).
lectrocardiographic and laboratory results. Significantly
etter ST-segment resolution was observed pre-PCI after
arly administration of abciximab (Table 3). After PCI,
ignificant more frequent complete ST-segment elevation
esolution at 60 min was also observed in the early group
50% vs. late group 35%; p  0.03) (Table 3).
The baseline levels of CK-MB (9 19 ng/ml vs. 10 18
g/ml) and troponin I (1  3 ng/ml vs. 1  2 ng/ml) were
imilar in early and late groups, respectively. Analysis of the
eak value and 48-h cumulative release for serum cardiac
l blush grade (MBG) (right) in the early versus late groups. Both parameters
de 3 and MBG 3 (left: p  0.001 vs. late group; right: p  0.028 vs. late group).Figure 2 TIMI Flow and MBG at Basal Angiography
Basal angiography: Thrombolysis In Myocardial Infarction (TIMI) flow (left) and myocardia
are significantly better in the early abciximab group with a higher percentage of TIMI flow grangiographic and Procedural Results
Table 2 Angiographic and Procedural Results
Early Group
(n  105)
Late Group
(n  105) p Value
Initial TIMI flow grade, n (%) 0.001*
0–1 63 (60) 88 (84)
2 17 (16) 6 (6)
3 25 (24) 11 (10)
Initial corrected TIMI frame count
(frames)
78 30 92 21 0.001†
Initial MBG, n (%) 0.02*
0 or 1 89 (85) 99 (94)
2 or 3 16 (15) 6 (6)
Final TIMI flow grade, n (%) NS*
0–1 4 (4) 5 (5)
2 4 (4) 3 (3)
3 97 (92) 97 (92)
Final corrected TIMI frame count
(frames)
27 19 32 23 0.09†
Final MBG, n (%) 0.001*
0 or 1 22 (21) 44 (42)
2 or 3 83 (79) 61 (58)
Multiple stents (%) 27 (26) 26 (25) NS*
Number of stents (%) 1.2 0.6 1.2 0.6 NS‡
Direct stenting (%) 31 (29) 14 (13) 0.004*
Drug-eluting stent (%) 37 (35) 41 (39) NS*
Intra-aortic balloon counterpulsation (%) 34 (32) 42 (40) NS*
Reference vessel diameter (mm) 3.2 0.4 3.2 0.5 NS‡
Initial minimal luminal diameter (mm) 0.1 0.3 0.05 0.1 0.005‡
Initial extent of stenosis (%) 95 11 98 5 0.01‡
Final minimal luminal diameter (mm) 3.1 0.7 3.0 0.7 NS‡
Final extent of stenosis (%) 5 16 6 15 NS‡
Length of stented segment (mm) 23 8 22 10 NS‡
Procedural time (min) 11 7 15 8 0.03‡
ata are presented as mean value SD or number (%) of patients. *Compared using Pearson chi-
quare or Fisher exact test; †compared using Mann-Whitney U test; ‡compared using unpaired
test.
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April 10, 2007:1517–24 Early Versus Late Abciximab in Primary PCIarkers revealed a more favorable trend in the early group
ith a lower release (Table 3).
ne-month LV function recovery and clinical out-
ome. After 1 month, we obtained 201 paired LV function
tudies. Even though regional and global LV function
arameters were similar at baseline, the increase of 1 month
MSI (early group 0.4  0.3 vs. late group 0.3  0.3, p 
.03) and the gain of EF (early group 8  7% vs. 6  7%,
 0.02) were significantly greater in the early group. This
roup of patients also presented a significantly better
MSI (1.4  0.3 vs. 1.5  0.4, p  0.01) and EF (51 
% vs. 47  10%, p  0.01) compared with the late group
Table 4, Fig. 3).
One-month clinical follow-up was available in all pa-
ients. Cumulative MACE occurred in 15 patients: 6 (5.7%)
n the early group and 9 (8.6%; p  0.42) in the late group.
ine patients (4.3%) died within 1 month, 3 (2.9%) patients
n the early group (1 from cardiogenic shock, 1 from sudden
eath, and 1 from fatal repeat AMI) and 6 patients (5.7%;
 0.49) in the late group (4 from cardiogenic shock, 1
rom free wall rupture, and 1 from fatal repeat AMI). Six
atients (2.8%), 2 in the early and 4 in the late group (p 
.68), had recurrent myocardial infarction. Three patients
1.4%), 2 in the early and 1 in the late group (p 0.62), had
epeated an urgent PCI, and 2 patients (0.9%), 1 in each
roup, underwent urgent coronary artery bypass grafting.
No differences were noted between the 2 groups with
egard to bleeding complications, which occurred in 9
Electrocardiographic and Laboratory Results
Table 3 Electrocardiographic and Laboratory
Percent preangiographic ST-segment elevation reduction
Percent 60-min post-PCI ST-segment elevation reduction
60-min post-PCI ST-segment elevation reduction 70% (%)
Basal CK-MB (ng/ml)
Peak CK-MB (ng/ml)
Cumulative 48-h CK-MB release (ng/ml·h)
Basal troponin I (ng/ml)
Peak troponin I (ng/ml)
Cumulative 48-h troponin I release (ng/ml·h)
Data are presented as mean value  SD or number (%) of patients. *
CK  creatine kinase; NS  not significant; PCI  percutaneous co
ne-Month Left Ventricle Function Recovery
Table 4 One-Month Left Ventricle Function Recovery
Early Group
(n  102)
Late Group
(n  99) p Value
Preprocedural EF (%) 42 8 41 8 NS*
Preprocedural WMSI 1.8 0.3 1.8 0.4 NS*
One month after PCI EF (%) 51 9 47 10 0.01*
One month after PCI WMSI 1.4 0.3 1.5 0.4 0.01*
One month after PCI mean gain EF (%) 8 7 6 7 0.02*
One month after PCI mean gain WMSI 0.4 0.3 0.3 0.3 0.03*
ata are presented as mean value  SD or number (%) of patients. *Compared using unpaired
test.S
EF  left ventricular ejection fraction; NS  not significant; PCI  percutaneous coronary
ntervention; WMSI  left ventricular wall motion score index.atients (8.6%) of the early group and in 6 patients (5.7%)
f the late group (p  0.44). Minor and major bleeding
istribution was not statistically different, with 8 minor
leeds (7.6%) in the early group and 5 (4.8%) in the late
roup (p  0.57) and 1 major bleed in each group (1%). No
ntracranial bleeding event was observed. There were no
ifferences in the blood transfusions: 6 (5.7%) patients in
he early group versus 4 (3.8%) patients of the late group
p  0.75). Thrombocytopenia after abciximab administra-
ion was seen in only 5 patients (2.4%), 1 (1%) in the early
roup and 4 (3.8%) in the late group (p  0.37).
iscussion
he results of the present trial suggest that, in patients with
rst AMI treated with PCI, early abciximab administration
n the emergency room compared with late in the catheter-
zation laboratory significantly improves preprocedural an-
iographic epicardial flow (evaluated by TIMI flow grade)
nd tissue perfusion (MBG 2 or 3). Moreover, post-
nterventional parameters of myocardial reperfusion (i.e.,
BG 2 and ST-segment resolution) were also improved,
nd this is associated with a smaller infarct size and with an
mproved LV function at 1-month follow-up.
Previous studies showed that primary PCI can be facili-
ated by intravenous abciximab to improve blood flow both
t the epicardial (3) and at the microcirculatory level (16).
he majority of large randomized trials demonstrated the
enefit of abciximab in AMI (1–4,16,17). De Luca et al. (6)
ecently showed that, compared with the control group,
djunctive abciximab is associated with a significant reduc-
ion of 30-day and long-term (6 to 12 months) mortality
4.4% vs. 6.2%, p  0.01) in patients undergoing primary
CI, without an increased risk of intracranial bleeding. In a
ecent pooled analysis of 6 studies (602 cases), comparing
arly versus late abciximab administration in AMI, the early
roup received abciximab a median of 50 min before
ngiography and had a higher proportion of pre-PCI TIMI
ow grade 3 (20% vs. 12%), quite similar to our findings (7).
oreover, the early group showed a significantly improved
ults
Early Group
(n  105)
Late Group
(n  105) p Value
14 30 4 22 0.010*
65 27 56 30 0.04*
53 (50) 37 (35) 0.03†
9 19 10 18 NS*
282 302 362 332 0.06*
6,483 6,834 8,087 6,648 0.09*
1 3 1 2 NS*
115 122 172 267 0.05*
3,329 3,481 4,165 4,076 0.09*
red using unpaired t test; †compared using Pearson chi-square.
intervention.ResT-segment resolution within 3 h after PCI and a moderate
b
m
t
t
e
f
i
a
f
fl
l
n
o
p
l
i
b
b
s
b
r
p
p
e
m
l
i
l
w
c
m
g
l
a
s
r
z
i
c
a
2
t
d
u
i
(
i
f
f
t
r
E
d
s
g
d
i
o
p
p
e
l
m
m
t
t
fl
p
1522 Maioli et al. JACC Vol. 49, No. 14, 2007
Early Versus Late Abciximab in Primary PCI April 10, 2007:1517–24ut nonsignificant reduction in the risk of death, new
yocardial infarction, or urgent target vessel revasculariza-
ion at 30 days. These data are consistent with the results of
he present trial, showing a better reduction in ST-segment
levation after PCI in the early group, mirrored by a
avorable trend in the clinical outcome at 1 month.
Observational data from the PAMI (Primary Angioplasty
n Myocardial Infarction) studies have indicated that,
mong patients who undergo successful primary PCI, LV
unction and survival appear to be improved when TIMI
ow grade 3 is present before intervention (18). Reasons
ikely include improved myocardial salvage as well as tech-
ically easier aspects of the intervention. In the early group
f this trial, the procedural time was shorter and the
roportion of direct stenting was higher compared with the
ate group, despite that mean lesion length was not signif-
cantly different between groups. A better IRA flow allows
etter visualization of lesion length, side branches, throm-
us burden, and distal arterial tree; this may facilitate all
teps of the procedure, including direct stenting, which has
een associated with less slow flow and better ST-segment
eduction (19).
Functional recovery is the main mechanism by which
atients with AMI benefit from various reperfusion thera-
ies, and it can be assessed by serial echocardiographic
valuations. In this trial, a better functional recovery at 1
onth was observed in the early group compared with the
ate group. This finding is probably correlated to a better
nitial angiographic outcome at epicardial and myocardial
evel, since the other baseline angiographic characteristics
ere similar between the 2 groups. Moreover, the postpro-
edural angiographic and electrocardiographic parameters of
yocardial reperfusion were also improved in the early
roup despite a similar procedural success at the epicardial
evel, as assessed by the QCA and the TIMI flow grade
nalyses. The results agreed with a previous study that
Figure 3 Left Ventricular Function According to Early and Late
Left ventricular function according to early (blue bars) and late (red bars) abcixima
and at 1 month after primary angioplasty, and mean gain in EF and WMSI between
significantly better compared with late abciximab patients (left: p  0.014 vs. late
(left: p  0.023 vs. late group) and in WMSI (right: p  0.031 vs. late group) washowed a strict correlation between the microvascular aeperfusion and the recovery of contraction in the infarct
one (12).
Although the single treatment with glycoprotein IIb/IIIa
nhibitors alone is not ideally suited to achieve early suc-
essful reperfusion, such observations recall the intrinsic
nticoagulant and fibrinolytic potential of abciximab (20–
2). In an experimental study, Goto et al. (20) have shown
hat antiglycoprotein IIb/IIIa agents possess the ability to
issolve platelet thrombi formed on the collagene surface
nder blood flow conditions. This effect might enhance
nfarct-artery patency before mechanical revascularization
23–25).
Thus, consistent with previous studies correlating early
nfarct-artery patency with both improved survival and LV
unction, early abciximab administration before PCI may
urther enhance treatment benefits. In the setting of facili-
ated PCI with full or reduced dose thrombolytic drugs, the
esults of ASSENT-4 PCI (Assessment of the Safety and
fficacy Of a New Treatment Strategy for Acute Myocar-
ial Infarction) trial (26) and a recent meta-analysis (27)
how that, despite the improvement of initial TIMI flow
rade 3, this approach is associated with increased rates of
eath, nonfatal reinfarction, urgent target vessel revascular-
zation, bleeding, and stroke. However, a worse clinical
utcome and an increased rate of stroke were not reported in
atients receiving facilitated regimes with platelet glyco-
rotein IIb/IIIa inhibitors alone (27).
Such findings support the design of the ongoing trial
xamining early pharmacologic reperfusion therapy fol-
owed by PCI (28). The positive effect of abciximab on
icrovascular flow can be explained by the prevention of
icrovascular obstruction potentially caused by emboliza-
ion of platelet aggregates and microthrombi (29,30). Fur-
hermore, abciximab markedly improves myocardial blood
ow regulation in acute coronary syndromes (31), and
reserves a coronary blood flow response to acetylcholine
imab
ction fraction (EF) (left) and wall motion score index (WMSI) (right) at baseline
time points. In the early abciximab patients, both functional parameters were
; right: p  0.014 vs. late group); in the same patients, the mean gain in EF
ficantly higher. Error bars indicate SDs of the mean.Abcix
b. Eje
the 2
group
signifter coronary stenting (32). The interaction of abciximab
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he Mac-1 receptor (35,36), may also play a role by
reventing leukocyte-mediated injury of microvessels, even-
ually related to reperfusion.
tudy limitations. This is a prospective, randomized,
ingle-center trial. The sample size of the population was
ot powered to detect differences in mortality or hard
linical end points. Another limitation of our trial was that
perator physicians were not blinded to the treatment
ssignment. Consequently, bias of the investigators cannot
e fully excluded as a factor influencing clinical treatment.
oreover, the event reporting was per investigators without
nvolvement of any independent adjudication committee.
owever, the physicians evaluating angiographic, electro-
ardiographic, and echocardiographic parameters were
linded to the assigned treatment. In this way, a possible
ias in the assessment of the end points was limited.
urthermore, the study was designed before the use of
lopidogrel loading dose as standard therapy in patients
ndergoing PCI.
onclusions. In patients with AMI treated with primary
CI, early abciximab administration improves pre-PCI
ngiographic findings and 1-month LV function, possibly
y starting early recanalization of the IRA.
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